Advertisement

Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients

  • P. E. Wallemacq
  • V. Furlan
  • A. Möller
  • A. Schäfer
  • P. Stadler
  • I. Firdaous
  • A -M. Taburet
  • R. Reding
  • S. Clement De Clety
  • J. De Ville De Goyet
  • E. Sokal
  • L. Lykavieris
  • V. Van Leeuw
  • O. Bernard
  • J. B. Otte
  • N. A. Undre
Article

Summary

The pharmacokinetics of intravenous and oral tacrolimus was assessed in paediatric liver transplant patients at two centers in Europe. Sixteen patients, age 0.7 to 13 years, participated in the study; 12 patients were evaluable for intravenous pharmacokinetics, and 16 for oral. Intravenous tacrolimus was given as a continuous 24 h infusion (mean 0.037±0.013 mg/kg/day), and oral tacrolimus was given in 2 doses per day (mean 0.152±0.015 mg/kg). Whole blood samples for the intravenous pharmacokinetic profile were taken before initiation of the first infusion, 4, 8, 12 and 24 h post-infusion, and every 24 h thereafter until intravenous administration was discontinued. During the 12 h wash-out period between intravenous and oral administration, samples were taken every 3 h. Samples for the oral pharmacokinetic profile were taken immediately before the first oral dose and 0.5, 0.75, 1, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-administration. Non-compartmental procedures were used to characterise the pharmacokinetic parameters. Mean estimates for clearance and terminal half-life were 2.3±1.2 ml/min/kg and 11.5±3.8 h, respectively, following intravenous tacrolimus. The mean bioavailability of oral tacrolimus was 25±20%. A strong correlation was observed between AUC and trough whole blood levels of tacrolimus (r=0.90). The clearance was approximately 2-fold higher than that previously observed in adults; this could explain the higher dosage requirements in children.

Keywords

Tacrolimus paediatric pharmacokinetics pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tzakis A.G., Reyes J., Todo S. et al. (1993): Two-year experience with FK 506 in pediatric patients. Transplant. Proc., 25, 619–621.PubMedGoogle Scholar
  2. 2.
    Inomata Y., Tanaka K., Egawa H. et al. (1996): The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation, 61, 247–252.CrossRefPubMedGoogle Scholar
  3. 3.
    Tzakis A.G., Reyes J., Todo S. et al. (1991): FK 506 versus cyclosporine in pediatric liver transplantation. Transplant. Proc., 23, 3010–3015.PubMedGoogle Scholar
  4. 4.
    McDiarmid S.V., Busuttil R.W., Ascher N.L. et al. (1995): FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the US multicenter trial. Transplantation, 59, 530–536.PubMedGoogle Scholar
  5. 5.
    Lee C., Jusko W., Shaefer M. et al. (1993): Pharmacokinetics of tacrolimus FK506 in transplant patients. Clin. Pharmacol. Ther., 53, 181.CrossRefGoogle Scholar
  6. 6.
    Undre N., Möller A., the FK 506 European Study Group. (1994): Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplantation patients. Transplant. Int., 7 (Suppl. 1), S15-S21CrossRefGoogle Scholar
  7. 7.
    Kobayashi M., Tamura K., Katayama N. et al. (1991): FK 506 assay past and present characteristics of FK 506 ELISA. Transplant. Proc., 3, 2725–2729.Google Scholar
  8. 8.
    Heinzel G., Woloszczak R., Thomann P. et al. (1993): TopFit: 2.0; pharmacokinetic and pharmacodynamic data analysis system for the PC. Berlin: Gustav Fischer. ISBN 3-437-11486-7.Google Scholar
  9. 9.
    Jain A.B., Fung J.J., Tzakis A.G. et al. (1991): Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant. Proc., 23, 2763–2766.PubMedGoogle Scholar
  10. 10.
    McDiarmid S.V., Colonna J.O., Shaked A. et al. (1993): Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation, 55, 1328–1332.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • P. E. Wallemacq
    • 1
  • V. Furlan
    • 2
  • A. Möller
    • 3
  • A. Schäfer
    • 3
  • P. Stadler
    • 3
  • I. Firdaous
    • 1
  • A -M. Taburet
    • 2
  • R. Reding
    • 1
  • S. Clement De Clety
    • 1
  • J. De Ville De Goyet
    • 1
  • E. Sokal
    • 1
  • L. Lykavieris
    • 1
  • V. Van Leeuw
    • 1
  • O. Bernard
    • 2
  • J. B. Otte
    • 1
  • N. A. Undre
    • 3
  1. 1.Service de Chirurgie PediatriqueUniversité Catholique de Louvain, Cliniques Universitaires Saint-LucBrusselsBelgium
  2. 2.Service d’HepatologieHôpital Kremlin-BicêtreParisFrance
  3. 3.Department of PharmacokineticsFujisawa GmbHMunichGermany

Personalised recommendations